Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

It has been close to two years since Narayana Health’s wholly owned subsidiary, Narayana Health Insurance—which has adopted a ‘managed heal...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

The oral drug, pociredir, was being tested ⁠to treat sickle-cell ⁠disease, an inherited blood disorder that can trigger pain, anemia and or...

After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...

Has a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...

The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to aff...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Pfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...

London’s FTSE 100 edged lower as losses in energy majors and AstraZeneca weighed on the index amid thin holiday trading. Weak crude prices ...

Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

Sun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...